Xerostomia Inventory (XI)
Also known as: Xerostomia Inventory (XI), XI Scale
The Xerostomia Inventory (XI) is an 11-item self-report questionnaire designed to measure subjective perception of dry mouth (xerostomia). Developed by Thomson and colleagues in 1999, it has become the standard validated instrument for assessing dry mouth severity in clinical practice and research. The XI captures both the frequency and severity of oral dryness symptoms and their impact on daily functioning, distinguishing symptomatic xerostomia from objective salivary gland dysfunction.
Key highlights
- Psychometrically robust with high internal consistency (Cronbach α = 0.85-0.91) and good test-retest reliability (ICC ≥ 0.79) across diverse samples
- Captures subjective perception independent of salivary flow measurements; clinically relevant because symptom burden and objective dysfunction do not always correlate
- Simple, efficient 11-item tool suitable for routine clinical use and large epidemiological surveys without respondent burden
- Valid across age groups, gender, and disease contexts (Sjögren's, post-cancer therapy, medication-induced); translated into 20+ languages with cross-cultural validation
- Sensitive to change; demonstrates responsiveness to salivary stimulant therapy and improvement over time in symptom-focused interventions
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
The XI is used in clinical settings to screen for symptomatic xerostomia in patients with autoimmune diseases (Sjögren's syndrome), head-and-neck cancer undergoing radiation or chemotherapy, polypharmacy patients, older adults, and those with systemic conditions affecting salivary glands. It is valuable in research evaluating xerostomia burden across populations, therapeutic trials of salivary stimulants or substitutes, and longitudinal tracking of symptoms during cancer treatment. The XI helps distinguish patients requiring intervention and enables monitoring of treatment response.
Strengths & limitations
- Psychometrically robust with high internal consistency (Cronbach α = 0.85-0.91) and good test-retest reliability (ICC ≥ 0.79) across diverse samples
- Captures subjective perception independent of salivary flow measurements; clinically relevant because symptom burden and objective dysfunction do not always correlate
- Simple, efficient 11-item tool suitable for routine clinical use and large epidemiological surveys without respondent burden
- Valid across age groups, gender, and disease contexts (Sjögren's, post-cancer therapy, medication-induced); translated into 20+ languages with cross-cultural validation
- Sensitive to change; demonstrates responsiveness to salivary stimulant therapy and improvement over time in symptom-focused interventions
- Subjective self-report; patients with cognitive impairment or severe aphasia may struggle with completion; not suited to non-verbal populations
- Does not identify etiology of xerostomia (autoimmune, medication-induced, radiation effect, etc.); requires clinical and laboratory assessment alongside XI results
- Recall period is typically over-the-past-month; may not capture acute changes in symptoms (e.g., within days of chemotherapy initiation)
- Ordinal scale; statisticians recommend non-parametric or ordinal regression analyses rather than treating as continuous, though many published studies use parametric methods
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What is the minimal clinically important difference (MCID) for the XI?
MCID estimates range from 4 to 8 points depending on population and context; a conservative estimate is 5 points. A change of ≥5 points is generally considered clinically meaningful improvement or worsening.
Can XI be administered to patients with cognitive impairment or dementia?
The XI relies on self-report and recall of symptom frequency; patients with moderate-to-severe cognitive impairment or non-verbal status may not complete reliably. Caregiver observation of behaviors (drinking water frequently, difficulty eating) can supplement clinical assessment but does not substitute XI.
How does XI relate to objective salivary flow rate?
Correlation between XI scores and salivary flow measurements is weak to moderate (r = 0.30-0.50). A high XI does not guarantee low flow, and vice versa. Both measures provide complementary information: XI captures patient experience, while flow rate reflects objective gland dysfunction.
Is the XI available in languages other than English?
Yes, the XI has been translated and validated in 20+ languages including Spanish, French, German, Italian, Swedish, Japanese, Turkish, and Hebrew. Use validated language versions; back-translation ensures semantic equivalence.
Sources
- 1.Thomson, W. M., Chalmers, J. M., Spencer, A. J., & Williams, S. M. (1999). The xerostomia inventory: A multi-item approach to measuring dry mouth. Community Dentistry and Oral Epidemiology, 27(6), 406-412.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). XI. ScholarGate. https://scholargate.app/dentistry/xerostomia-inventory